.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Argus Health
Teva
Cantor Fitzgerald
Daiichi Sankyo
Julphar
US Department of Justice
Harvard Business School
Farmers Insurance
Healthtrust

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090212

« Back to Dashboard
NDA 090212 describes ADENOSINE, which is a drug marketed by West-ward Pharms Int, Luitpold, Sagent Strides, Emcure Pharms Ltd, Wockhardt, Teva Pharms Usa, Fresenius Kabi Usa, Mylan Labs Ltd, Akorn, Gland Pharma Ltd, and Hospira Inc, and is included in seventeen NDAs. It is available from fifteen suppliers. Additional details are available on the ADENOSINE profile page.

The generic ingredient in ADENOSINE is adenosine. There are twenty-six drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the adenosine profile page.

Summary for 090212

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 090212

Mechanism of ActionAdenosine Receptor Agonists

Medical Subject Heading (MeSH) Categories for 090212

Suppliers and Packaging for NDA: 090212

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ADENOSINE
adenosine
SOLUTION;IV (INFUSION) 090212 ANDA Sagent Pharmaceuticals 25021-307 25021-307-20 1 VIAL in 1 CARTON (25021-307-20) > 20 mL in 1 VIAL
ADENOSINE
adenosine
SOLUTION;IV (INFUSION) 090212 ANDA Sagent Pharmaceuticals 25021-307 25021-307-21 10 VIAL in 1 CARTON (25021-307-21) > 20 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;IV (INFUSION)Strength60MG/20ML (3MG/ML)
Approval Date:Mar 28, 2014TE:APRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;IV (INFUSION)Strength90MG/30ML (3MG/ML)
Approval Date:Mar 28, 2014TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Accenture
Federal Trade Commission
Chinese Patent Office
Cerilliant
Express Scripts
Cantor Fitzgerald
Novartis
AstraZeneca
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot